Will Knee Injections Help Your Osteoarthritis? Here’s What the Evidence Says

Why It Matters

The findings curb costly, poorly supported injection use and steer patients toward interventions with proven health and economic value. This shifts spending in orthopaedic care and reduces exposure to unnecessary procedural risks.

Key Takeaways

• Corticosteroid shots help pain for up to six weeks only.
• Hyaluronic acid offers minimal benefit and higher serious adverse risk.
• PRP shows mixed results; costs $200‑$600 per injection in US.
• Stem cell injections lack solid evidence and cost around $3,300 per dose.
• Exercise, weight loss, and OTC NSAIDs remain most effective, evidence‑backed treatments.

Pulse Analysis

Knee osteoarthritis remains a leading source of disability, affecting roughly one in twelve adults in Australia and a comparable share of the U.S. population. The condition’s chronic pain drives a booming market for intra‑articular injections, with clinics charging $200‑$600 per platelet‑rich plasma (PRP) shot and upwards of $3,300 for a single stem‑cell dose. While these procedures are marketed as joint‑repair solutions, the underlying science is still emerging, and regulatory oversight varies widely across jurisdictions. Understanding the true cost‑benefit ratio is essential for patients, insurers, and policymakers navigating a landscape crowded with hype.

Clinical guidelines now draw a clear line between short‑term relief and long‑term disease modification. Corticosteroid injections can blunt inflammation during flare‑ups, but their analgesic effect wanes after six weeks and repeated use may accelerate cartilage loss. Large systematic reviews have dismissed hyaluronic acid as offering negligible improvement and a higher incidence of serious adverse events, leading to its exclusion from most treatment algorithms. PRP, despite its biologic appeal, yields inconsistent outcomes; some trials report modest pain reduction, while others find no advantage over placebo. The lack of standardized preparation protocols further muddies the evidence pool, making it difficult for clinicians to prescribe a reliable regimen.

Given the limited and often transient benefits of injectable therapies, the most cost‑effective strategy continues to be non‑pharmacologic care. Structured exercise programs, targeted weight reduction, and judicious use of over‑the‑counter NSAIDs are supported by high‑quality research and confer additional health gains beyond knee pain relief. For patients considering injections, a thorough appraisal of the financial outlay, potential risks, and realistic expectations is crucial. As higher‑quality trials on PRP and stem cells progress, the medical community will be better positioned to integrate any proven advances, but until then, the prudent path remains grounded in evidence‑based, low‑cost interventions.